Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BIOMARIN PHARMACEUTICAL INC

Get SEC filing alerts via email and in your feed for BIOMARIN PHARMACEUTICAL INC

BMRN

BIOMARIN PHARMACEUTICAL INC

About BIOMARIN PHARMACEUTICAL INC

BioMarin Pharmaceutical Inc. is a global biotechnology company specializing in developing and commercializing therapies for rare genetic diseases. Its core products include enzyme replacement therapies and gene therapies targeting conditions like mucopolysaccharidosis, achondroplasia, phenylketonuria, Batten disease, and hemophilia A. BioMarin serves patients worldwide through direct sales and partnerships, leveraging proprietary biologics, gene therapy platforms, and a strong intellectual property portfolio to address unmet medical needs in specialized markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BIOMARIN PHARMACEUTICAL INC

1
1
BIOMARIN PHARMACEUTICAL INC BioMarin Reports Q1 2026 Financial Results with $766.2M Revenue and Amicus Acquisition

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
BIOMARIN PHARMACEUTICAL INC BioMarin Reports $3.2 Billion Revenue, Announces Amicus Therapeutics Acquisition

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
BIOMARIN PHARMACEUTICAL INC BioMarin Reports Q3 2025 Revenue Growth but Net Loss Amid Rising Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BIOMARIN PHARMACEUTICAL INC BioMarin Pharmaceutical Reports 15.9% Revenue Growth to $825.4 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BIOMARIN PHARMACEUTICAL INC BioMarin Pharmaceutical Reports 15% Revenue Growth to $745.1 Million in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BIOMARIN PHARMACEUTICAL INC BioMarin Pharmaceutical Reports 19.9% Revenue Growth to $2.9 Billion for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
BIOMARIN PHARMACEUTICAL INC BioMarin Pharmaceutical Reports Significant Revenue and Profit Growth in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments